|Date||30 December 2020 – present|
|Cause||COVID-19 pandemic in Singapore|
|Participants||10,818,023 total doses administered (as of 27 October 2021)|
|Part of a series on the|
COVID-19 vaccination in Singapore is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Singapore is currently the most-vaccinated country in the world, with more than 87% of its total population (and more than 91% of its eligible populace) having completed their vaccination regimen.
The Singapore Government invested more than one billion Singapore dollars to sign advanced purchase agreements and made early down payments on promising vaccine candidates, such as Pfizer BioNTech, Moderna and CoronaVac.
On 5 October 2020, the Singapore Government appointed a 14-member Expert Committee on COVID-19 Vaccination, which was to advise and assess on the efficacy and safety of COVID-19 vaccines for use in Singapore.On 24 December 2020, the Expert Committee submitted its recommendations on the overall vaccination strategy of Singapore to the government. In its recommendations, they highlighted that two groups of people had to be priortised for vaccination: people who are at high risk of infection, the frontline healthcare workers; and people who are vulnerable of severe diseases and complications from infections, the elderly. The Committee continued to advise on the use of vaccines as the pandemic continues. It recommended booster shots for people above 60 of age as evidence of declining effacy of vaccination over time emerged, and updated recommendations for those with mild skin reactions after first dosage to continue their vaccination programme.
On 14 December 2020, Singapore became the first Asian country to approve Pfizer-BioNTech's coronavirus vaccine.The first shipment of the vaccine arrived seven days later on 21 December.
Singapore also received its first shipment of Sinovac Biotech's CoronaVac vaccine, on 22 December 2020. However, the vaccine was not authorised for use by the Health Sciences Authority (HSA).On 2 June 2021, MOH approved the Sinovac vaccine for used in private healthcare settings so people, who are not suitable to take the mRNA vaccines, can take the Sinovac vaccine. However, since the China-made vaccine is not part of the national programme, those who choose to receive it will not be eligible for the Vaccine Injury Financial Assistance Programme (VIFAP) should they develop any adverse reactions.
On 30 December 2020, Singapore became the first country in Asia to start its COVID-19 vaccination campaign. The vaccine is free for all Singaporeans and long-term residents. Health workers, other frontline workers and seniors were the first inoculated with the vaccine jointly developed by BioNTech and Pfizer.
On 3 February 2021, Singapore also became the first country in Asia to approve Moderna's COVID-19 vaccine, jointly developed by the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and Moderna.
On 18 May, the Health Ministry announced that those who register for COVID-19 vaccination from 19 May onwards will have their second dose scheduled six to eight weeks after the first, instead of three to four weeks later.This change in strategy was aimed to have 400,000 more people in Singapore to be given at least one vaccine dose by end-July so that virtually all eligible Singapore residents will get at least one dose by early August. However, as vaccine supplies continue to arrive as planned and most of the population who are willing to take the vaccine will have received their first dose by the second half of July, MOH announced on 29 June that the interval between the first and second doses of the COVID-19 vaccine would revert to four weeks. This was part of the efforts to ensure that more of the population will be fully vaccinated earlier. On 9 July, it was announced that the interval between doses of the Pfizer-BioNTech vaccine would be further shortened to 3 weeks. It was further added that those who had previously taken a vaccine not approved under the National Vaccination Programme would be advised to take 2 doses of the approved ones.
The Health Sciences Authority (HSA) also approved the use of the Pfizer-BioNTech coronavirus vaccine for children aged 12 to 15; previously, it was given only to those aged 16 years and above. It was granted interim authorization by the HSA under the Pandemic Special Access Route in December 2020.
On 24 June, the Health Ministry concluded a purchase agreement with Novavax for its non-mRNA COVID-19 vaccine, with shipments expected to arrive in Singapore before the end of 2021.
On 28 July, IHH Healthcare Singapore obtained approval to import the Sinopharm BIBP vaccine (BBIBP-CorV) via the special access route (SAR).The SAR was set up on 31 May to allow individuals to choose vaccines not under the national inoculation program.
On 2 August, Senior Minister of State for Health Janil Puthucheary announced in Parliament that those who suffered allergic reactions after receiving the first dose of an mRNA COVID-19 vaccine will be invited to receive the Sinovac CoronaVac vaccine and will be deemed as fully vaccinated individuals.
On 6 August, the Health Ministry announced it shall recognize all COVID-19 vaccines listed under the Emergency Use Listing (EUL) by the World Health Organization (WHO) starting from 10 August 2021. This means that Singapore recognizes all individuals that have been inoculated with a WHO-approved vaccine as fully vaccinated individuals and shall be accorded vaccination-differentiated safe management measures and travel concessions.
On 20 September, an additional 101,000 doses of the Sinovac vaccine was delivered.
On 23 October, the Health Sciences Authority (HSA) granted interim authorization under the Pandemic Special Access Route for the CoronaVac vaccine under a three-dose regime, following which it was included in the National Vaccination Programme. Those who are ineligible to take either of the approved mRNA vaccines would be invited for this vaccine and eligible for the Vaccine Injury Financial Assistance Programme (VIFAP).
On 10 December, the Health Sciences Authority approved the use of the Pfizer-BioNTech coronavirus vaccine for children aged 5 to 11 with the first shots to be given by end-2021. At the same time, Pfizer-BioNTech coronavirus vaccine is approved for full registration.The first shipment of the paediatric vaccine arrived seven days later on 22 December with the first shots given on 27 December.
Singapore started the rolling out of booster shots for senior citizens above 60 years of age from 14 September 2021.Subsequently, from 4 October, it will start giving booster shots for the eligible population above 50 years of age, followed by individuals above 30 years of age from 9 October. The eligible population should have their second dose taken before 6 months. From 24 November, eligible population who completed their second dose before 5 months can get booster shots for all age groups. On 10 December, the use of booster shots is extended to individuals above 18 years of age starting from 14 December.
On 19 August 2021, the Immigration and Checkpoints Authority (ICA) shall issue a tamper-proof vaccination sticker that is to be pasted onto their travel documents and can serve as proof of vaccination. The issuance of this special sticker will be limited to travelers who have been vaccinated with a COVID-19 vaccine under the Emergency Use Listing (EUL) by the World Health Organization (WHO) and the presentation of a valid English-language vaccination certificate.
On 24 September 2021, Malaysian National Recovery Council chairman Muhyiddin Yassin confirmed that Malaysia and Singapore would recognise each other's vaccination certificates in order to facilitate travel between the two countries.
|Pfizer–BioNTech/Comirnaty||Approved for use||unknown||14 December 2020 (EUA)||30 December 2020||Pfizer and BioNTech||-|
|Moderna||Approved for use||unknown||3 February 2021 (EUA)||17 March 2021||Moderna||-|
|CoronaVac||Approved for use||301,000||23 October 2021 (EUA)||4 June 2021||Sinovac|
|Sinopharm BIBP||Partially approved||unknown||28 July 2021 (EUA)||30 August 2021||Sinopharm||-|
|Johnson&Johnson/Janssen||Partially approved||unknown||10 August 2021 (EUA)||Pending||Janssen||-|
|Oxford–AstraZeneca/AZD1222/Covishield||Partially approved||unknown||10 August 2021 (EUA)||Pending||University of Oxford and AstraZeneca|
|Covaxin||Partially approved||unknown||3 November 2021 (EUA)||Pending||Bharat Biotech||-|
|Novavax||Partially approved||unknown||17 December 2021 (EUA)||Pending||Novavax|
CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech and for its development collaborated with American company Pfizer, for support with clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom. As 31 December, 90% of adults and young people over 12 have received their first dose, 82% have received their second and 59% have received their third.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Israel's COVID-19 vaccination programme, officially named "Give a Shoulder", began on 19 December 2020, and has been praised for its speed, having given twenty percent of the Israeli population the first dose of the vaccines' two dose regimen in the span of three weeks.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.
The National COVID-19 Immunisation Programme, abbreviated as NIP or PICK, is a national vaccination campaign that is currently being implemented by the Malaysian government as an approach in curbing the spread of coronavirus disease 2019 (COVID-19) and to end the COVID-19 pandemic in Malaysia by successfully achieving the highest immunisation rate among its citizens and non-citizens that are residing in Malaysia. It is the largest immunisation programme implemented in the history of the country and it is being administrated by The Special Committee For Ensuring Access To COVID-19 Vaccine Supply (JKJAV) since early 2021.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020; mass vaccinations began on December 14, 2020. The Moderna vaccine was granted emergency use authorization on December 17, 2020, and the Janssen vaccine was granted emergency use authorization on February 27, 2021. By April 19, 2021, all U.S. states had opened vaccine eligibility to residents aged 16 and over. On May 10, 2021, the FDA approved the Pfizer-BioNTech vaccine for adolescents aged 12 to 15. On August 23, 2021, the FDA granted full approval to the Pfizer–BioNTech vaccine for individuals aged 16 and over.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The COVID-19 virus was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
COVID-19 vaccination in New Zealand began on 20 February 2021, and will continue throughout the year with the goal of vaccinating all willing New Zealanders aged 12 or older. As of 1 September, anyone in New Zealand, regardless of their immigration status, is eligible to be vaccinated.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.
COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.
The COVID-19 vaccination campaign in Turkey began on 14 January 2021. As of 12 November 2021, 55.789.131 people have received their first dose, and 49.543.627 people have been fully vaccinated.
The following is a timeline of the COVID-19 pandemic in Singapore in 2021.
This article documents the chronology of the response to the COVID-19 pandemic in December 2021, which originated in Wuhan, China in December 2019. Some developments may become known or fully understood only in retrospect. Reporting on this pandemic began in December 2019.